Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial

Aim To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) in patients with type 2 diabetes treated with once-weekly subcutaneous dulaglutide versus placebo. Materials and Methods Patients without electrocardiographic (ECG)-confirmed AA at baseline and rando...

Full description

Saved in:
Bibliographic Details
Institution:Universidad EIA
Main Authors: Raubenheimer, Peter J., Cushman, William C., Avezum, Alvaro, Basile, Jan, Conget, Ignacio, Dagenais, Gilles, Hoover, Anastasia, Jansky, Petr, Lanas, Fernando, Leiter, Lawrence A., Lopez-Jaramillo, Patricio, Pogosova, Nana, Probstfield, Jeffrey, Rao-Melacini, Purnima, Ryden, Lars, Sheu, Wayne H.-H., Temelkova-Kurktschiev, Theodora, Gerstein, Hertzel C., Masira
Format: Artículo de revista
Language:English
Published: Diabetes, Obesity and Metabolism 2022-01-04
Online Access:https://repositorio.udes.edu.co/handle/001/6086
Tags: Add Tag
No Tags, Be the first to tag this record!